Edit Content

Miglustat 100 mg

Miglustat is one of the enzyme inhibitor drugs and is used in the treatment of Gaucher disease type 1. In this disease, a series of fatty substances are not broken down and accumulate in the body, causing problems in the liver, spleen, bones, and blood.

Extended-Release Capsule: 100mg

42 Capsules in a box

Stock Code : d6716038a457 Category :

Fampiron is used in adult patients living with multiple sclerosis to improve walking. It belongs to a group of medicines called potassium channel blockers. They work by stopping potassium leaving the nerve cells which have been damaged by multiple sclerosis. This medicine is thought to work by letting signals pass down the nerve more normally, allowing people to walk better.



Therapeutic Fields​


improvement in walking-related activities

Fampridine-ER may also improve other clinical symptoms of MS such as:

  • Fatigue

  • Optic Neuritis

  • Nystagmus:

  • Episodic ataxia:

  • Lambert-Eaton myasthenic syndrome

Fampiron-ER Front
Dosing and Adminstration

The recommended dose is one 10 mg tablet, twice daily.

maximum daily dose: 20 mg.

The tablets should be taken without food.

Missed Dose:

The usual dosing regimen should always be followed. A double dose should not be taken if a dose is missed.

Patients with renal impairement:

  • Mild renal imparement (CrCl 51-80 ml/min): no dose adjustment needed; however, use with extreme caution as risk of seizure may be increased secondary to reduced clearance.
  • Moderate-to-severe renal impairement: (CrCl≤ 50 ml/min): use is contraindicated.

Patients with hepatic impairment

No dose adjustment is required; drug undergoes minimal metabolism and is primarily excreted unchanged in the urine.

Paediatric population:

The safety and efficacy of Fampridine in children aged under 18 have not been established. No data are available.

Pregnancy category: C

breast feeding:

It is unknown whether fampridine is excreted in human or animal milk. Fampridine is not recommended during breastfeeding.


  • Hypersensitivity to fampridine or to any of the excipients.
  • Concurrent treatment with other medicinal products containing fampridine (4-aminopyridine).
  • Patients with prior history or current presentation of seizure.
  • Patients with moderate or severe renal impairment (creatinine clearance <50 ml/min).
  • Concomitant use of Fampyra with medicinal products that are inhibitors of Organic Cation Transporter 2 (OCT2) for example, cimetidine.

Side Effects

Adverse reactions identified include urinary tract infection, seizure, insomnia, anxiety, balance disorder, dizziness,paraesthesia, tremor, headache and asthenia.

We understand the complexities and challenges you face in the healthcare industry. That’s why we’re dedicated to providing innovative solutions and insightful knowledge to help you achieve your goals.

Your input is crucial in helping us understand your needs and deliver the most relevant support:

Related Products